Vanguard Capital Management’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
Other funds holding DYN
Vanguard Capital Management's DYN Position: Q3 2026 in Review
Vanguard Capital Management increased its Dyne Therapeutics (DYN) stake by 20% in Q3 2026, buying an estimated $28.5M and bringing the position to 7,552,313 shares worth $122M. The position accounts for ﹤0.01% of the portfolio, ranked #1414.
Vanguard Capital Management first reported a position in DYN in Q1 2026 and has held it in 3 quarters since. The position peaked at $140M in Q2 2026. 268 funds tracked by Wall St. Rank hold DYN as of Q3 2026.
- Vanguard Capital Management held 7,552,313 shares of Dyne Therapeutics worth $122M as of Q3 2026.
- Vanguard Capital Management bought 1,241,344 Dyne Therapeutics shares in Q3 2026, an estimated $28.5M.
- Dyne Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1414 holding.
- Vanguard Capital Management first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Dyne Therapeutics position peaked at $140M in Q2 2026.
- 268 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.